DrugPatentWatch Database Preview
Details for Patent: 9,782,402
Try a free trial
See Plans and Pricing
Which drugs does patent 9,782,402 protect, and when does it expire?
Patent 9,782,402 protects SUBLOCADE and is included in one NDA.
This patent has thirty-eight patent family members in twenty-seven countries.
Summary for Patent: 9,782,402
| Title: | Injectable composition comprising buprenorphine |
| Abstract: | The present invention is directed to a buprenorphine sustained release delivery system capable of delivering buprenorphine, a metabolite, or a prodrug thereof for a duration of about 14 days to about 3 months. The buprenorphine sustained release delivery system includes a flowable composition and a solid implant for the sustained release of buprenorphine, a metabolite, or a prodrug thereof. The implant is produced from the flowable composition. The buprenorphine sustained release delivery system provides in situ 1-month and 3-month release profiles characterized by an exceptionally high bioavailability and minimal risk of permanent tissue damage and typically no risk of muscle necrosis. |
| Inventor(s): | Norton; Richard L. (Fort Collins, CO), Watkins; Andrew (Fort Collins, CO), Zhou; Mingxing (Fort Collins, CO) |
| Assignee: | Indivior UK Limited (Berkshire, GB) |
| Application Number: | 15/334,000 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Formulation; Compound; |
Drugs Protected by US Patent 9,782,402
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Indivior Inc | SUBLOCADE | buprenorphine | SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS | 209819-001 | Nov 30, 2017 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | Y | TREATING ADDICTION BY SUBCUTANEOUS INJECTION OF BUPRENORPHINE | ➤ Sign Up | |||
| Indivior Inc | SUBLOCADE | buprenorphine | SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS | 209819-001 | Nov 30, 2017 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | Y | TREATING ADDICTION WITH 100 MG OR 300 MG DOSE OF BUPRENORPHINE | ➤ Sign Up | |||
| Indivior Inc | SUBLOCADE | buprenorphine | SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS | 209819-001 | Nov 30, 2017 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | Y | TREATING OPIOID ADDICTION BY ADMINISTERING BUPRENORPHINE | ➤ Sign Up | |||
| Indivior Inc | SUBLOCADE | buprenorphine | SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS | 209819-001 | Nov 30, 2017 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | Y | TREATING ADDICTION BY ONCE PER MONTH ADMINISTRATION OF BUPRENORPHINE | ➤ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 9,782,402
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2011263478 | ➤ Sign Up | |||
| Brazil | 112012031290 | ➤ Sign Up | |||
| Canada | 2801676 | ➤ Sign Up | |||
| Chile | 2012003462 | ➤ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
